Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intas Builds Europe Scale With £603m Teva Deal

Executive Summary

Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.

You may also be interested in...

Time Is Of The Essence As Teva Considers European Assets Bids

Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.

Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A

Aurobindo Pharma reported a subdued Q1 but investors remained upbeat on the firm’s prospects as it transitions to a larger complex generics play. The company also emphasized its “disciplined” M&A approach; it has no interest in chasing “exotic” deals.

India Pharma 2017: 3Cs And D (Disruption)?

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts